Health conditions
GLP-1s and thyroid conditions
October 2, 2026 · 6 min read · Medically reviewed by Bryan Milton, MD · Reviewed October 2, 2026
The boxed warning concerns one specific thyroid cancer, not thyroid disease generally. What is contraindicated, what is not, and the levothyroxine question.
Thyroid questions come up constantly here and are frequently answered wrongly in both directions — people with hypothyroidism told they cannot take a GLP-1, and people with a relevant family history not asked about it. The distinction on the label is specific.
What the boxed warning actually says
The approved semaglutide and tirzepatide labels carry a boxed warning about thyroid C-cell tumors observed in rodent studies. Whether that finding translates to humans has not been determined. What follows from it on the label is specific: these medications are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC), or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Medullary thyroid carcinoma is an uncommon, specific thyroid cancer arising from C-cells. It is not the same as the more common thyroid cancers, and it is not thyroid disease in general.
What is and is not a contraindication
| Condition | Position |
|---|---|
| Personal or family history of MTC | Contraindicated on the approved labels |
| Multiple Endocrine Neoplasia syndrome type 2 | Contraindicated on the approved labels |
| Hypothyroidism / Hashimoto's | Not a listed contraindication; tell your clinician, and see the levothyroxine note |
| Hyperthyroidism / Graves' | Not a listed contraindication; disclose it as part of your history |
| Thyroid nodules or goitre | Not automatically a contraindication; a clinician assesses it |
| Other thyroid cancers | Not the cancer in the boxed warning; raise it so it is assessed properly |
A clinician assesses the specifics rather than applying the word 'thyroid' as a blanket rule in either direction.
The levothyroxine question
If you take levothyroxine, this is worth raising. It is a medication where absorption and timing genuinely matter, and GLP-1s delay gastric emptying. That does not mean the two cannot be combined — they frequently are — but it does mean whoever manages your thyroid should know you have started a GLP-1, and that any monitoring they do should continue.
What not to do is change your levothyroxine timing or dose on your own. That decision belongs to its prescriber.
Why thyroid function is worth knowing anyway
Because thyroid disease causes fatigue, weight change, hair shedding, constipation and cold intolerance — the same symptoms people attribute to a GLP-1. Someone with untreated hypothyroidism who starts a GLP-1 and feels exhausted has two plausible explanations and no way to tell them apart without a blood test. That is one of the main reasons a clinician may want thyroid function checked, and lab orders are included at no extra cost at GLP when a clinician requests them.
What to report while on treatment
A lump or swelling in the neck, hoarseness, new trouble swallowing, or persistent shortness of breath. The labels direct that these be evaluated, because they are the symptoms the boxed warning is about. Tell your care team promptly rather than at your next check-in.
Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. The boxed warning and contraindications apply to compounded preparations of the same molecule, and GLP's clinicians screen against them.
Whether a GLP-1 is appropriate for you, with your particular history and medications, is a decision for a licensed clinician who has reviewed them. This article is here so you know what to raise, not so you can conclude.
This article is educational and is not a substitute for personalized medical advice. Whether any medication is appropriate for you is a decision for a licensed clinician who has reviewed your health history.